Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: The National Health Commission said on Monday that 78 new asymptomatic cases had been identified as of the end of Sunday, compared with 47 the day before. Imported cases and asymptomatic patients, who show no symptoms but can still pass the virus on, have become China’s chief concern after draconian containment measures succeeded in slashing the overall infection rate. Hubei province, the original epicentre, accounted for almost half the new asymptomatic cases. A total of 705 people with asymptomatic cases were under medical observation around mainland China. The surge in asymptomatic cases, which China only began reporting last week, poses a worry as Hubei’s capital Wuhan prepares to allow people to leave the city on April 8 for the first time since it was locked down in late January. Wuhan officials revoked the “epidemic-free” status of 45 residential compounds due to the emergence of asymptomatic cases and other unspecified reasons, according to a report on Monday by the official Xinhua news agency. “Epidemic-free” status allows people living in Wuhan compounds to leave their homes for two hours at a time. China has now reported a total of 81,708 cases, with 3,331 deaths. One new locally transmitted infection was reported in the latest data, in the southern province of Guangdong, down from five a day earlier in the same province. China has closed its borders to foreigners as the virus spreads globally, though most imported cases have involved Chinese nationals returning from overseas. It began testing all international arrivals for the coronavirus from April 1, customs official Song Yueqian said. Of the new cases showing symptoms, 38 entered China from abroad, compared with 25 a day earlier. Of those, 20 arrived in the northeastern province of Heilongjiang from neighbouring Russia. All were Chinese citizens who had flown from Moscow to Vladivostok and travelled to China overland. China will work to prevent cases being imported through land borders, the government said after a meeting chaired by Premier Li Keqiang on Monday，which noted the number of such cases had exceeded cases recorded at airports recently. Those who try to hide their travel history or health condition face a fine of up to 30,000 yuan ($4,230) or even criminal proceedings, Song said, adding such people will be placed on a customs “blacklist” of travellers who will be subject to tighter checks in future. Another possible source of infection are the 1.6 million Chinese who study overseas, many of whom have struggled to return home since international flights were reduced. Charter flights are being arranged to bring home Chinese students in the United States, starting with the youngest, China’s embassy in Washington said. The ambassador, Cui Tiankai, noted in the New York Times on Monday there had been “unpleasant talk” between the two countries about the virus. “But this is not the time for finger-pointing. This is a time for solidarity, collaboration and mutual support,” Cui wrote. Amid criticism China was too slow to warn the international community about the outbreak, Xinhua on Monday published a “detailed timeline” of the country’s coronavirus response and information sharing, from late December 2019 to March 2020. China started reporting to the United States “regularly” on the epidemic and containment measures from Jan. 3, according to the timeline. Click here for an interactive GRAPHIC tracking global spread of coronavirus
[A]: China sees rise in asymptomatic coronavirus cases, to tighten controls at land borders.


[Q]: Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.
[A]: Eli Lilly drops inhaled insulin program.


[Q]: “Even though the majority of strokes and heart attacks occur in people who are 65 and older, studies have found that cholesterol-lowering drugs are not prescribed as often for older people as they are for younger people,” Dr. Seemant Chaturvedi of Wayne State University in Detroit, Michigan, said in a statement. “These results show that using these drugs is just as beneficial for people who are over 65 as they are for younger people.”   In April, British researchers reported in the New England Journal of Medicine that treating high blood pressure in people 80 and older cut their risk of fatal strokes and other heart problems. Statins cut the risk of heart attack or stroke by lowering levels of fatty substances such as low-density lipoprotein, or “bad” cholesterol, and triglycerides. They also raise levels of high-density lipoprotein or “good” cholesterol. They include atorvastatin, made by Pfizer Inc under the brand name Lipitor; pravastatin or Pravachol, made by Bristol-Myers Squibb; fluvastatin, made by Novartis AG under the brand name Lescol, and several others. Seemant and colleagues studied 4,731 people 18 and older who had a recent stroke or a mini-stroke as part of a study sponsored by Pfizer. About half were over 65, with an average age of 72. The other half were under 65 and had an average age of 54. In each age group, about half were taking Lipitor and the other half were on a placebo. The statin worked equally well in both groups, the researchers reported in the journal Neurology. It lowered LDL cholesterol by about 61 points in the group of older patients and by about 59 points in the younger age group. Stroke is the No. 3 killer in the United States behind heart disease and cancer. The U.S. Centres for Disease Control and Prevention estimate 780,000 Americans will have strokes this year. They will kill 150,000 people and permanently disable 15 percent to 30 percent of survivors.
[A]:
Statins fight stroke in older people too.